Nazem Atassi

5.5k total citations
68 papers, 2.2k citations indexed

About

Nazem Atassi is a scholar working on Neurology, Genetics and Cellular and Molecular Neuroscience. According to data from OpenAlex, Nazem Atassi has authored 68 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 58 papers in Neurology, 30 papers in Genetics and 12 papers in Cellular and Molecular Neuroscience. Recurrent topics in Nazem Atassi's work include Amyotrophic Lateral Sclerosis Research (51 papers), Neurogenetic and Muscular Disorders Research (27 papers) and Parkinson's Disease Mechanisms and Treatments (15 papers). Nazem Atassi is often cited by papers focused on Amyotrophic Lateral Sclerosis Research (51 papers), Neurogenetic and Muscular Disorders Research (27 papers) and Parkinson's Disease Mechanisms and Treatments (15 papers). Nazem Atassi collaborates with scholars based in United States, Germany and Spain. Nazem Atassi's co-authors include Merit Cudkowicz, David Schoenfeld, Sabrina Paganoni, James D. Berry, Marco L. Loggia, Jacob M. Hooker, Nicole R. Zürcher, Eric A. Macklin, Bruce R. Rosen and Michael Benatar and has published in prestigious journals such as PLoS ONE, Neurology and Stroke.

In The Last Decade

Nazem Atassi

67 papers receiving 2.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Nazem Atassi United States 29 1.4k 804 526 397 337 68 2.2k
Pierre‐François Pradat France 30 2.6k 1.8× 1.5k 1.9× 669 1.3× 364 0.9× 396 1.2× 77 3.4k
Gaëlle Bruneteau France 25 1.3k 0.9× 817 1.0× 386 0.7× 219 0.6× 211 0.6× 58 1.8k
Lora Clawson United States 24 1.8k 1.2× 901 1.1× 592 1.1× 309 0.8× 239 0.7× 36 2.6k
Angela Genge Canada 25 921 0.6× 477 0.6× 495 0.9× 231 0.6× 152 0.5× 96 1.6k
Michael A. van Es Netherlands 30 2.7k 1.9× 1.5k 1.8× 1.0k 2.0× 468 1.2× 643 1.9× 83 3.6k
Stefano Zoccolella Italy 24 1.3k 0.9× 510 0.6× 357 0.7× 186 0.5× 206 0.6× 78 1.9k
Dale J. Lange United States 31 2.3k 1.6× 563 0.7× 500 1.0× 633 1.6× 201 0.6× 85 3.4k
Tomoko Kurata Japan 27 752 0.5× 218 0.3× 1.2k 2.2× 396 1.0× 372 1.1× 87 2.5k
Sang‐Wuk Jeong South Korea 25 892 0.6× 432 0.5× 712 1.4× 148 0.4× 316 0.9× 59 2.6k
João Siffert United States 22 485 0.3× 389 0.5× 454 0.9× 208 0.5× 117 0.3× 51 1.8k

Countries citing papers authored by Nazem Atassi

Since Specialization
Citations

This map shows the geographic impact of Nazem Atassi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nazem Atassi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nazem Atassi more than expected).

Fields of papers citing papers by Nazem Atassi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nazem Atassi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nazem Atassi. The network helps show where Nazem Atassi may publish in the future.

Co-authorship network of co-authors of Nazem Atassi

This figure shows the co-authorship network connecting the top 25 collaborators of Nazem Atassi. A scholar is included among the top collaborators of Nazem Atassi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nazem Atassi. Nazem Atassi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hincelin-Méry, Agnès, Cathy Cantalloube, Robert J. Pomponio, et al.. (2023). Safety, pharmacokinetics, and target engagement of a brain penetrant RIPK1 inhibitor, SAR443820 (DNL788), in healthy adult participants. Clinical and Translational Science. 17(1). e13690–e13690. 21 indexed citations
2.
Wooten, Dustin, Laura Ortiz-Terán, Xiaomeng Zhang, et al.. (2019). Multi-Modal Signatures of Tau Pathology, Neuronal Fiber Integrity, and Functional Connectivity in Traumatic Brain Injury. Journal of Neurotrauma. 36(23). 3233–3243. 18 indexed citations
3.
Schoenfeld, David, Dianne M. Finkelstein, Eric A. Macklin, et al.. (2019). Design and analysis of a clinical trial using previous trials as historical control. Clinical Trials. 16(5). 531–538. 12 indexed citations
4.
Benatar, Michael, Joanne Wuu, Peter M. Andersen, et al.. (2018). Randomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressive SOD1 ALS. Neurology. 90(7). e565–e574. 101 indexed citations
5.
Xing, Fangxu, Jerry L. Prince, Maureen Stone, et al.. (2018). Strain map of the tongue in normal and ALS speech patterns from tagged and diffusion MRI. PubMed. 9413. 36–36. 4 indexed citations
6.
Paganoni, Sabrina, Mohamad J. Alshikho, Nicole R. Zürcher, et al.. (2017). Imaging of glia activation in people with primary lateral sclerosis. NeuroImage Clinical. 17. 347–353. 26 indexed citations
7.
Alshikho, Mohamad J., Nicole R. Zürcher, Marco L. Loggia, et al.. (2017). Integrated [11C]-PBR28 MR-PET imaging in Amyotrophic Lateral Sclerosis (P3.139). Neurology. 88(16_supplement). 1 indexed citations
8.
Atassi, Nazem, Maosheng Xu, Christina Triantafyllou, et al.. (2017). Ultra high-field (7tesla) magnetic resonance spectroscopy in Amyotrophic Lateral Sclerosis. PLoS ONE. 12(5). e0177680–e0177680. 46 indexed citations
9.
Paganoni, Sabrina, Katharine Nicholson, James Chan, et al.. (2017). Urate levels predict survival in amyotrophic lateral sclerosis: Analysis of the expanded Pooled Resource Open‐Access ALS clinical trials database. Muscle & Nerve. 57(3). 430–434. 39 indexed citations
10.
Jahandideh, Samad, Albert A. Taylor, Danielle Beaulieu, et al.. (2017). Longitudinal modeling to predict vital capacity in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 19(3-4). 294–302. 9 indexed citations
11.
Fournier, Christina, Hiroshi Mitsumoto, Catherine Lomen‐Hoerth, et al.. (2016). Primary Lateral Sclerosis and Early Upper Motor Neuron Disease. Journal of Clinical Neuromuscular Disease. 17(3). 99–105. 17 indexed citations
12.
Zach, Neta, Nazem Atassi, Adriano Chiò, et al.. (2016). The ALS Stratification Prize-Using the Power of Big Data and Crowdsourcing for Catalyzing Breakthroughs in Amyotrophic Lateral Sclerosis (ALS) (P5.102). Neurology. 86(16_supplement). 1 indexed citations
13.
Delnomdedieu, Marielle, Sridhar Duvvuri, Nazem Atassi, et al.. (2016). First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer’s disease. Alzheimer s Research & Therapy. 8(1). 12–12. 42 indexed citations
14.
Nicholson, Katharine, Sabrina Paganoni, Amy M. Shui, et al.. (2015). Urate Levels Predict Disease Progression and Survival in Amyotrophic Lateral Sclerosis (ALS). (P6.100). Neurology. 84(14_supplement).
15.
Berry, James D., Sabrina Paganoni, Nazem Atassi, et al.. (2015). A Phase IIa Double-Blind, Placebo-Controlled Study to Evaluate the Safety of Oral Fingolimod In Patients with Amyotrophic Lateral Sclerosis (ALS) (P7.067). Neurology. 84(14_supplement). 1 indexed citations
16.
Zürcher, Nicole R., Marco L. Loggia, Robert Lawson, et al.. (2015). Increased in vivo glial activation in patients with amyotrophic lateral sclerosis: Assessed with [11C]-PBR28. NeuroImage Clinical. 7. 409–414. 175 indexed citations
17.
Ratti, Elena, James D. Berry, Nazem Atassi, et al.. (2014). Predictors of Outcome in Amyotrophic Lateral Sclerosis (P2.076). Neurology. 82(10_supplement). 1 indexed citations
18.
Quinn, Colin, Eric A. Macklin, Nazem Atassi, et al.. (2013). Post-lumbar puncture headache is reduced with use of atraumatic needles in ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 14(7-8). 632–634. 5 indexed citations
19.
Yu, Hong, et al.. (2013). Regional Pattern of Symptom Spread in Amyotrophic Lateral Sclerosis (ALS) (P06.130). Neurology. 80(7_supplement). 1 indexed citations
20.
Atassi, Nazem, Merit Cudkowicz, & David Schoenfeld. (2011). Advanced statistical methods to study the effects of gastric tube and non-invasive ventilation on functional decline and survival in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis. 12(4). 272–277. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Pierre‐François Pradat Breakdown of academic impact, for papers by Gaëlle Bruneteau Breakdown of academic impact, for papers by Lora Clawson Breakdown of academic impact, for papers by Angela Genge Breakdown of academic impact, for papers by Michael A. van Es Breakdown of academic impact, for papers by Stefano Zoccolella Breakdown of academic impact, for papers by Dale J. Lange Breakdown of academic impact, for papers by Tomoko Kurata Breakdown of academic impact, for papers by Sang‐Wuk Jeong Breakdown of academic impact, for papers by João Siffert
Rankless by CCL
2026